A total of 9% of placebo recipients contracted COVID-19 from a household member, compared with 3% of ensitrelvir recipients, ...

UVA School of Medicine emeritus professor Dr. Frederick G. Hayden helped design the trial and presented the results Wednesday ...

Back in 2021, at the height of the pandemic, scientists at Pfizer revealed the development of a novel antiviral molecule, ...

An international clinical trial has identified a medication that can help prevent symptomatic COVID-19 in people exposed ...

As the H5N1 avian influenza outbreak continues, scientists are working to better understand the virus's threat to human ...

Scientists have found that an oral antiviral drug successfully prevents monkeys from dying after an Ebola infection, an advance that may prevent future outbreaks of the deadly virus. The Ebola virus ...

New research this month shows that the experimental antiviral obeldesivir prevented up to 100% of deaths in monkeys infected ...

Based upon a successful engagement with the US Food and Drug Administration (FDA) at the End-of-Phase 2 meeting in January 2025, Atea is initiating a global Phase 3 program and expects patient ...

Cocrystal Pharma (NASDAQ:COCP – Get Free Report) is expected to release its earnings data before the market opens on Thursday, March 27th. Analysts expect Cocrystal Pharma to post earnings of ($0.55) ...

August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new ...